Brief: Histogen Inc Says Top-Line Data For Phase 1 Study Of Emricasan In Mild-Symptomatic Covid-19 Patients Anticipated In June 2021
03/06/2021 13:24
June 3 (Reuters) - Histogen Inc HSTO.O :
* HISTOGEN INC - TOP-LINE DATA FOR PHASE 1 STUDY OF
EMRICASAN IN
MILD-SYMPTOMATIC COVID-19 PATIENTS ANTICIPATED IN JUNE 2021
* HISTOGEN INC - HST 004 SELECTED AS PRODUCT CANDIDATE FOR
SPINAL
DISC REPAIR WITH IND ENABLING ACTIVITIES UNDERWAY
* HISTOGEN INC - HST 003 TRIAL FOR CARTILAGE REGENERATION IN
KNEE
REMAINS ON-TRACK WITH AN ANTICIPATED PHASE 1/2 STUDY INITIATION
IN JUNE 2021
Source text for Eikon: ID:nGNX2m4GLJ
Further company coverage: HSTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up